The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …

Immune checkpoint blockade therapy targeting programmed cell death protein 1 (PD-1) has
revolutionized the landscape of multiple human cancer types, including head and neck …

Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …

Lung cancer is a leading cause of cancer-related deaths worldwide. About 10–30% of
patients with non-small cell lung cancer (NSCLC) harbor mutations of the EGFR gene. The …

Lung cancer is the leading cause of cancer-related deaths worldwide. Immune checkpoint
inhibitors, including monoclonal antibodies against programmed death-1 (PD-1) and …

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …

Although immune checkpoint inhibitors (ICIs) that target programmed cell death protein-
1/programmed cell death ligand-1 axis have significantly shifted the treatment paradigm in …

Abstract Background Immune checkpoint inhibitors (ICIs) have improved cancer outcomes.
However, immune-related adverse effects are common. The aim was to investigate the …

The epidermal growth factor receptor (EGFR) pathway is a well-studied oncogenic pathway
in human non-small cell lung cancer (NSCLC). A subset of advanced NSCLC patients (15 …